Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors Read more about Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
ZEJULA® (niraparib) has been nominated for the Prix Galien USA Award for Best Pharmaceutical Product Read more about ZEJULA® (niraparib) has been nominated for the Prix Galien USA Award for Best Pharmaceutical Product
Posters from Zai Lab, GSK/Tesaro, Macrogenics and Novocure will be presented at the ESMO Congress 2019 Read more about Posters from Zai Lab, GSK/Tesaro, Macrogenics and Novocure will be presented at the ESMO Congress 2019
Novocure Announces 10 Oral Presentations and a Special Session on Tumor Treating Fields at the 41st International Engineering in Medicine and Biology Conference Read more about Novocure Announces 10 Oral Presentations and a Special Session on Tumor Treating Fields at the 41st International Engineering in Medicine and Biology Conference
Medicare Releases Final Local Coverage Determination Providing Coverage of Optune® for Newly Diagnosed Glioblastoma Read more about Medicare Releases Final Local Coverage Determination Providing Coverage of Optune® for Newly Diagnosed Glioblastoma
MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer Read more about MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
Paratek Pharmaceuticals Broadens Clinical Profile of NUZYRA™ (Omadacycline) with New ECCMID 2019 Data Presentations Read more about Paratek Pharmaceuticals Broadens Clinical Profile of NUZYRA™ (Omadacycline) with New ECCMID 2019 Data Presentations
The Lancet Oncology Publishes Results from Phase 2 QUADRA Clinical Trial of Niraparib Read more about The Lancet Oncology Publishes Results from Phase 2 QUADRA Clinical Trial of Niraparib
Entasis Therapeutics Announces Multiple Data Presentations at ECCMID 2019 Read more about Entasis Therapeutics Announces Multiple Data Presentations at ECCMID 2019
Paratek Pharmaceuticals Presenting New Data from NUZYRA™ (Omadacycline) Development Program at ECCMID 2019 Read more about Paratek Pharmaceuticals Presenting New Data from NUZYRA™ (Omadacycline) Development Program at ECCMID 2019